The active ingredient in Incruse Ellipta is umeclidinium bromide [1]. Umeclidinium bromide is a long-acting muscarinic antagonist (LAMA) [1][2].
What is umeclidinium bromide used for?
Umeclidinium bromide, the active component of Incruse Ellipta, is a bronchodilator used for the long-term, once-daily maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD) [1][2]. It works by relaxing the muscles around the airways in the lungs, which helps to open them up and make breathing easier [2].
How does Incruse Ellipta work in the lungs?
Incruse Ellipta delivers umeclidinium bromide to the lungs. Umeclidinium is a selective, reversible antagonist of muscarinic acetylcholine receptors M3. In the airways, M3 receptors are located on smooth muscle, and their activation by acetylcholine leads to bronchoconstriction [2]. By blocking M3 receptors, umeclidinium inhibits acetylcholine-induced bronchoconstriction, leading to bronchodilation and improved airflow [2].
What are the other components in Incruse Ellipta?
Besides umeclidinium bromide, Incruse Ellipta contains inactive ingredients necessary for the dry powder inhaler formulation. These include lactose and magnesium stearate [1]. Lactose is used as a carrier for the active ingredient, and magnesium stearate acts as a lubricant [1].
Can Incruse Ellipta be used for asthma?
Incruse Ellipta is indicated for the maintenance treatment of airflow obstruction in patients with COPD. It is not indicated for the treatment of asthma [1][2].
When does the patent for Incruse Ellipta expire?
Information regarding specific patent expiry dates for Incruse Ellipta, including its active ingredient umeclidinium bromide, is available through resources like DrugPatentWatch.com [3]. Patent information is complex and can involve multiple patents covering different aspects of a drug, such as the active ingredient, formulation, and manufacturing process. These patents can have varying expiry dates, and litigation can impact market exclusivity [3].